Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer
about
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersMolecular therapy of colorectal cancer: progress and future directionsSystems biology approaches for advancing the discovery of effective drug combinationsPhase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Beyond RAS and BRAF: a target rich disease that is ripe for pickingBioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateThe MAPK pathway across different malignancies: a new perspective.SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumorsEstablishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer.p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerNFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer.Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia.Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.Therapeutic Approaches to RAS Mutation.The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.NFATc3 mediates the sensitivity of gastric cancer cells to arsenic sulfide.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer.β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
P2860
Q26781362-E99330E2-3DAE-4DD0-9E65-25DBCFE3620AQ27005764-CE5072BB-E314-4335-97D2-CB8954EFCC2FQ27702922-1902D7ED-9187-4FF6-B299-879335A51BAFQ27853084-5D797135-1681-4754-91A5-9C56B2EE1767Q28066095-05734A27-96C6-4029-8AC2-4F46288C20E4Q34103108-FB269245-8096-408E-BBA8-D47F00DA505EQ34441837-1DFF3B65-1484-490B-91E1-26601BB6ADC9Q34459097-FA4DFCDD-CB88-451C-90C1-25286D6B2E2DQ35035656-043A0899-E2DF-4704-8341-57B2199E6C8BQ35119526-78BC3083-5B16-4A95-8478-8038DA4BBB15Q35587605-D4F59AB7-80D4-44BE-8D8C-CFDDA899E427Q35630191-7CBF9039-CBC4-4967-8167-9389BF65FB6BQ35745893-E30372A1-C411-4AAF-A462-48E8A05EBFC8Q36093878-A048552B-CF2D-4D2A-A5AE-E5C18A0EBAD3Q36544152-C4BF4619-11D9-486C-9A03-E276E7EBF8FCQ36562360-32578992-847E-4A70-9478-1156F065DB16Q37122874-63530FB8-C0CA-4443-BAA8-97D1563D7654Q38743421-DB5EAA09-34DA-41C6-AF0C-CC472E7F2FF9Q38953475-4DC0168D-1F5B-4571-A98C-2FE014178C12Q41592878-D9CABC8D-3AAB-430B-9BB9-9F7768084EF2Q41694346-D3514F0D-3491-4627-9CF5-6239AB8A468DQ47167566-26B2F888-872A-43CD-8AF6-0DB0225092FBQ49547317-8A7D4B22-9037-4CF3-A103-AE6E3460BB5CQ50296864-011EB518-5FE9-49D8-9529-4C2B29E204BEQ51176917-B7EA3BF3-E08F-4A8D-B6EB-B876A56131CAQ53765363-5FF3A157-862A-4DAD-B139-F1E2E5F2D765Q57156789-F7879D77-3E0F-48B7-BF68-51C4F300FA95
P2860
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rational combination of a MEK ...... al models of colorectal cancer
@en
Rational combination of a MEK ...... l models of colorectal cancer.
@nl
type
label
Rational combination of a MEK ...... al models of colorectal cancer
@en
Rational combination of a MEK ...... l models of colorectal cancer.
@nl
prefLabel
Rational combination of a MEK ...... al models of colorectal cancer
@en
Rational combination of a MEK ...... l models of colorectal cancer.
@nl
P2093
P2860
P1476
Rational combination of a MEK ...... al models of colorectal cancer
@en
P2093
Aik Choon Tan
Anna Spreafico
Daniel L Gustafson
Heather M Selby
James V Degregori
John J Arcaroli
John J Tentler
Kelly L McPhillips
Lindsey N Micel
P2860
P304
P356
10.1158/1078-0432.CCR-12-3140
P407
P577
2013-06-11T00:00:00Z